HALOTEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALOTEX (HALOTEX).
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
| Metabolism | Haloprogin is primarily metabolized in the liver via oxidation and conjugation, with minimal systemic absorption following topical application. |
| Excretion | Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%). |
| Half-life | Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Not established; likely low due to high protein binding and lipophilicity. |
| Bioavailability | Topical: negligible systemic absorption (<0.5% of applied dose); oral: not available. |
| Onset of Action | Topical: relief of pruritus and improvement in lesions typically within 24-72 hours of application. |
| Duration of Action | Topical: symptomatic improvement persists as long as treatment continues; recurrence common without adequate course (typically 2-4 weeks). |
| Molecular Weight | 361.44 Da |
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment needed; topical use with minimal systemic absorption. |
| Liver impairment | No adjustment needed; topical use with minimal systemic absorption. |
| Pediatric use | Safety not established; use only if clearly needed. |
| Geriatric use | No specific adjustments; monitor for irritation. |
| 1st trimester | Avoid during first trimester unless clearly needed; no adequate studies in pregnant women. |
| 2nd trimester | Use only if potential benefit justifies potential risk to the fetus; limited data available. |
| 3rd trimester | Use near term only if clearly needed; risk of neonatal respiratory depression with topical application unlikely. |
Clinical note
Comprehensive clinical and safety monograph for HALOTEX (HALOTEX).
| Placental transfer | Minimal to no expected placental transfer due to low systemic absorption after topical use; no data on injection or oral forms. |
| Breastfeeding | Although systemic absorption is minimal after topical application, it is not known whether haloprogin is excreted in human milk. Caution is advised, and the lowest effective dose should be used. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to haloprogin or any component of the formulation
| Precautions | For external use only. Avoid contact with eyes and mucous membranes. Discontinue if irritation or sensitization occurs. Use with caution in patients with known hypersensitivity to haloprogin or any component of the formulation. |
| Food/Dietary | No known food interactions. Topical use minimizes systemic absorption. |
| Clinical Pearls | HALOTEX (haloprogin) is a topical antifungal for dermatophyte and Candida infections. Apply to affected area twice daily for 2-4 weeks post-resolution to prevent recurrence. Avoid occlusive dressings unless directed. Not for nail or scalp use. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Haloprogin (HALOTEX) is a topical antifungal. Systemic absorption is minimal, and no teratogenic effects have been reported in animal studies. There are no adequate well-controlled studies in pregnant women. Risk to the fetus is considered low when applied topically as directed. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required for topical haloprogin use. Observe for local irritation or allergic reaction. |
| Fertility Effects | No known effects on fertility based on limited data. Systemic absorption is negligible. |
| Patient Advice | Apply a thin layer to clean, dry skin twice daily. · Continue use for at least 2 weeks after symptoms resolve to prevent recurrence. · Do not cover treated areas with bandages or wraps unless instructed. · Avoid contact with eyes, mouth, or mucous membranes. · Report signs of irritation or allergic reaction (rash, burning, swelling). · Do not use on nails or scalp; this medicine is for skin only. |